JAZZ News and Press, Jazz Pharmaceuticals plc From 09/12/23

2023-09-12 07:40:45 ET More on Jazz Pharmaceuticals Seeking Alpha’s Quant Rating on Jazz Pharmaceuticals Jazz Pharmaceuticals: Depressed Valuation Opens Up Potential Jazz Pharmaceuticals: Xywav Debate Continued Drag On Equity Performance Jazz Pharma wi...

Jazz Pharmaceuticals Announces Key Update to Leadership Team PR Newswire Renée Galá promoted to President and Chief Operating Officer DUBLIN , Sept. 12, 2023 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that Renée...

Jazz Pharmaceuticals Showcases Impact of Sleep Medicine Portfolio at Psych Congress 2023 PR Newswire Six presentations demonstrated Jazz's commitment to providing solutions for people living with difficult-to-treat sleep disorders Review of multiple clinical trials...

2023-09-11 03:06:49 ET Summary Zymeworks is a biotech company focused on developing therapies for hard-to-treat cancers. Its lead product, zanidatamab, has shown promising results in clinical trials and has been partnered with larger pharmaceutical companies. The company also ...

2023-09-04 07:46:14 ET Summary Zymeworks, a biotech firm, specializes in biotherapeutics for cancers, with primary product zanidatamab targeting HER2 and collaborations with BeiGene and Jazz Pharmaceuticals. Financially robust with $431.4M cash, revenue surged due to a Jazz deal, ...

Jazz Pharmaceuticals to Participate in Citi's 18th Annual BioPharma Conference PR Newswire DUBLIN , Aug. 24, 2023 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the Company will participate in the Citi Annual BioPharma Conferenc...

2023-08-16 03:00:21 ET Summary Baupost Group's 13F portfolio value decreased from $5.85B to $5.61B this quarter. The portfolio is heavily concentrated, with Liberty Global, Liberty Media Sirius XM, ViaSat, Alphabet, and Veritiv accounting for approximately 58% of the holdings. ...

2023-08-09 21:53:04 ET Jazz Pharmaceuticals plc (JAZZ) Q2 2023 Results Conference Call August 09, 2023 04:30 PM ET Company Participants Andrea Flynn - VP & Head, IR Bruce Cozadd - Chairman and Chief Executive Officer Renee Gala - Executive Vice President and ...

2023-08-09 16:09:03 ET Jazz Pharmaceuticals press release ( NASDAQ: JAZZ ): Q2 Non-GAAP EPS of $4.51 beats by $0.08 . Revenue of $957.32M (+2.6% Y/Y) beats by $15.16M . Raised full year 2023 financial guidance: Raised total and Neuroscience revenue guidance...

Jazz Pharmaceuticals Announces Second Quarter 2023 Financial Results and Raises 2023 Full Year Financial Guidance PR Newswire – Strong execution delivered second quarter 2023 total revenues of $957 million – – Commercial excellence drove continued adop...